Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong

被引：0
|
作者：
Loong, H. H. [1 ]
Wong, C. K. H. [2 ]
Leung, L. K. S. [3 ]
Chan, C. P. K. [4 ]
Chang, A. [5 ]
Gibbs, M. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Novartis Oncol Hong Kong, Med Affairs, Hong Kong, Peoples R China
[5] Novartis Oncol Hong Kong, Market Access, Hong Kong, Peoples R China
[6] Novartis Oncol, Dubai, U Arab Emirates
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ALECTINIB, BRIGATINIB, AND LORLATINIB AS FIRST-LINE THERAPIES FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS
    Mudumba, R.
    Nieva, J. J.
    Padula, W.
    VALUE IN HEALTH, 2024, 27 (12) : S81 - S81
  • [22] Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Tan, Wan Hui Gloria
    Toh, Chee-Keong
    Loke, Lydia Pui Yee
    Pearce, Fiona
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 952 - 960
  • [23] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [24] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [25] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [26] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [27] COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN UNITED STATES
    Zhang, Y.
    Shao, Y.
    Shi, L.
    VALUE IN HEALTH, 2020, 23 : S32 - S32
  • [28] The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective
    Cranmer, Holly
    Kearns, Isabella
    Young, Melanie
    Humphries, Michael J.
    Trueman, David
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 970 - 979
  • [29] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [30] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
12345